Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Kit Dillon and Wirecutter Staff A road trip is an adventure. It doesn’t matter ...